PMC8270715_01
Hematoxylin and eosin staining and immunohistochemical staining of tissue from the renal biopsy in Case 1 (x400).
CRIU2021-9936330.001.jpg
PMC8270715_01_CRIU2021-9936330.001.jpg
fig1
A biopsy of the left renal mass was performed, and pathological analysis revealed collecting duct carcinoma (CDC) (PAX8+, Vimentin+, and CD10-) (Figure 1).
Computed tomography (CT) findings in Case 1. Abdominal CT showed no change in the right primary renal tumor or bone metastasis after four cycles of immunotherapy.
CRIU2021-9936330.002.jpg
PMC8270715_01_CRIU2021-9936330.002.jpg
fig2
After completion of two cycles of the combination immunotherapy, computed tomography (CT) revealed a slight enlargement of the primary tumor and bone metastases but showed no change during the two additional cycles of the combination therapy or the nivolumab monotherapy (Figure 2).
PMC8270715_02
Hematoxylin and eosin staining and immunohistochemical staining of tissue from the renal biopsy in Case 2 (x400).
CRIU2021-9936330.003.jpg
PMC8270715_02_CRIU2021-9936330.003.jpg
fig3
Pathological analysis of a biopsy specimen of the right renal mass revealed CDC (CK19+, PAX8+, and CD10-) (Figure 3).
Computed tomography (CT) findings in Case 2 showing new lesions in the lung after two cycles of immunotherapy, which shrank following the two additional cycles.
CRIU2021-9936330.004.jpg
PMC8270715_02_CRIU2021-9936330.004.jpg
fig4
After two additional cycles, all the tumors shrank markedly (Figure 4).